[18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors

Choi, Seung Jin; Kim, Jae Seung; Kim, Jeong Hoon; Oh, Seung Jun; Lee, Jeong Gyo; Kim, Chang‐Jin; Shin, Y. H.; Yeo, Jun Sang; Ryu, Jin Sook; Moon, Dae Hyuk

doi:10.1007/s00259-004-1742-3

Cited by 171 publications

(93 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although 18 F-FLT appears to have limited sensitivity, uptake of 18 F-FLT by tumors correlates with Ki-67, a common proliferation index used ex vivo, as demonstrated in several extracranial cancers (92)(93)(94)(95)(96). 18 F-FLT uptake has also been investigated in brain tumors, and similar correlations have been observed (97)(98)(99)(100)(101)(102). Thus, 18 F-FLT has the potential to monitor treatment response and to serve as a prognostic marker.…”

Section: Other Pet Tracers and Future Directions 18 F-flt Petmentioning

confidence: 70%

Clinical Applications of PET in Brain Tumors

Chen

2007

Journal of Nuclear Medicine

391

209

View full text Add to dashboard Cite

Malignant gliomas and metastatic tumors are the most common brain tumors. Neuroimaging plays a significant role clinically. In low-grade tumors, neuroimaging is needed to evaluate recurrent disease and to monitor anaplastic transformation into high-grade tumors. In high-grade and metastatic tumors, the imaging challenge is to distinguish between recurrent tumor and treatmentinduced changes such as radiation necrosis. The current clinical gold standard, MRI, provides superior structural detail but poor specificity in identifying viable tumors in brain treated with surgery, radiation, or chemotherapy. 18 F-FDG PET identifies anaplastic transformation and has prognostic value. The sensitivity and specificity of 18 F-FDG in evaluating recurrent tumor and treatment-induced changes can be improved significantly by coregistration with MRI and potentially by delayed imaging 3-8 h after injection. Amino acid PET tracers are more sensitive than 18 F-FDG in imaging recurrent tumors and in particular recurrent low-grade tumors. They are also promising in differentiating between recurrent tumors and treatment-induced changes.

show abstract

Section: Other Pet Tracers and Future Directions 18 F-flt Petmentioning

confidence: 70%

Clinical Applications of PET in Brain Tumors

Chen

2007

Journal of Nuclear Medicine

391

209

View full text Add to dashboard Cite

show abstract

“…In the brain, as the surrounding normal structures has a very low proliferation rate, attempts have been made to use these markers to better identify the tumour margin. 18F-fluorothymidine (FLT) is actively taken up into dividing cells and has an excellent contrast-to-background ratio [76][77][78]. The area of abnormality is larger than the abnormality seen on MR [77].…”

Section: Cellular Proliferationmentioning

confidence: 99%

Imaging biomarkers of brain tumour margin and tumour invasion

Price

Gillard²

2011

BJR

View full text Add to dashboard Cite

ABSTRACT. Invasion of tumour cells into the normal brain is one of the major reasons of treatment failure for gliomas. Although there is a good understanding of the molecular and cellular processes that occur during this invasion, it is not possible to detect the extent of the tumour with conventional imaging. However, there is an understanding that the degree of invasion differs with individual tumours, and yet they are all treated the same. Newer imaging techniques that probe the pathological changes within tumours may be suitable biomarkers for invasion. Imaging methods are now available that can detect subtle changes in white matter organisation (diffusion tensor imaging), tumour metabolism and cellular proliferation (using MR spectroscopy and positron emission tomography) occurring in regions of tumour that cannot be detected by conventional imaging. The role of such biomarkers of invasion should allow better delineation of tumour margins, which should improve treatment planning (especially surgery and radiotherapy) and provide information on the invasiveness of an individual tumour to help select the most appropriate therapy and help stratify patients for clinical trials.

show abstract

“…18 F-FLT is metabolized by thymidine kinase 1 and, thus, is a marker for DNA synthesis. Its uptake correlates better with Ki-67 proliferation index compared with 18 F-FDG [49]. In recurrent disease 18 F-FLT performed better compared with 18 F-FDG in detecting tumor tissue and was a better predictor for disease progression and survival.…”

Section: Imaging Of Specific Biological Processes Of Brain Tumors Witmentioning

confidence: 89%